R&D DATA INTELLIGENCELEADERS FORUM

Ramada P l a za Hote l - Ba se l , Sw i t ze r l andJanuar y 24-26th, 2017

5 EVENTS IN ONE:

Hear keynote presentations from the experts:

with more than 40 presentations from R&D Data Experts

DAY 1:STRATEGIC DEVELOPMENTS IN R&D BIG DATA

DAY 2 - STREAM 1:DISCOVERY & OMICS DATA EXCELLENCE

DAY 2 - STREAM 2:CLINICAL & PATIENT-LEVEL DATA EXCELLENCE

DAY 3 - STREAM A:R&D IT & BIOINFORMATICS

DAY 3 - STREAM B:DIGITAL R&D HEALTH COLLABORATIONS

FOURTH ANNUAL | LIFE SCIENCE

John WiseExecutive DirectorPistoia Alliance, UK

Prof. Michel GoldmanInstitute for Interdisciplinary Innovation in healthcareUniversité Libre de Bruxelles, Belgium

Paul GrundyChief Medical Officer & Director Healthcare TransformationIBM Healthcare and Life Sciences, USA

Barbara VoithHead Global Clinical Sciences OperationsBayer AG, Germany

Chinnappa KodiraHead of Bioinformatics, Diagnostics, Imaging and Biomedical Technologies, GE Global Research, USA

Christine BienvenuFounderSuis(s)ePatiente, Switzerland

Dipak KalraPresident, EuroRec InstituteProfessor, Health InformaticsUCL, UK

Eric SteagerDirector - Corporate Development & Innovation Managing Director, Strategic Innovation PortfolioIndependence Blue Cross, USA

This Event is Certified forContinuing Professional Development

Sandy FarmerExecutive Director, Enterprise Science & Technology OperationsPfizer Worldwide R&D, USAJohan LuthmanVP Neuroscience Clinical Development, Eisai, USABarbara VoithHead Global Clinical Sciences OperationsBayer AG, GermanyPeter SpeyerGlobal Head of Real World Evidence SolutionsNovartis, SwitzerlandMichael RebhanSenior InvestigatorNovartis Institutes for BioMedical Research, SwitzerlandChinnappa KodiraHead of Bioinformatics, Diagnostics, Imaging and Biomedical TechnologiesGE Global Research, USAPieter PeetersSenior Director, Computational Biology – Discovery Sciences, Janssen, BelgiumAnka G. EhrhardtDirector Clinical Cytometry, CTTO, ECTR, BMS, USAHelge WeissigDirector, BioinformaticsActivX Biosciences, USAArmin FurtwaenglerGlobal Senior Medical Director Respiratory; Global Team Leader Medical AffairsBoehringer Ingelheim, Germany (TBC)Jan BreemansSenior Director, Head Global Data ServicesGrunenthal, BelgiumEric NeumannVP of Knowledge Informatics Foundation Medicine, USA

Nigel HughesScientific Director, RMEDS, Quantitative SciencesJanssen, BelgiumMark DaviesModelling and Simulation ScientistRoche, SwitzerlandHans MartensRegional Privacy Manager EuropeGSK, NetherlandsHenning KuichIT Project Manager for Early Research, Bayer, GermanyNevenka DimitrovaCTO Genomics, Healthcare IT, Philips Research, USAMollie Shields UehlingPresident & CEOSAFE-BioPharma Association, USASvetlana PidashevaDirector, Scientific Communications and Publications Established Products and Emerging MarketsSanofi Biosurgery, USADavid HeardHead of Digital HealthMylan, SwitzerlandSimone BreitkopfHead Governmental and Public Affairs Pricing and ReimbursementAlcon Laboratories, GermanyHank WuDirector, Digital Strategy & Innovation | Digital Health Tech & Data SciencesBiogen, USAWarren WinkelmanSenior Medical Director and Head of Medical Innovation, Nestlé Skin Health (SHIELD), USAJohn GlasspoolEVP, Head of Corporate Strategy and Customer OperationsBaxalta, USA

Speaker sOver v iew

John WiseExecutive DirectorPistoia Alliance, UKProf. Michel GoldmanInstitute for Interdisciplinary Innovation in healthcareUniversité Libre de Bruxelles, BelgiumDipak KalraPresident, EuroRec InstituteProfessor, Health InformaticsUCL, UKFrancis CrawleyExecutive DirectorGood Clinical Practice Alliance – Europe, BelgiumJulia WilsonAssociate Director ExternalRelationsWellcome Trust Sanger Institute & Global Alliance for Genomics and Health, UK

Stephen KeenanData and Security Working Group Manager for Global Alliance for Genomics and HealthEuropean Bioinformatics Institute, UKAng DaviesLecturer in Healthcare Sciences, Clinical Bioinformatics and Genomic Medicine Programme Director, University of Manchester, UKTorsten SchwedeProfessor, BioinformaticsBiozentrum University Basel & Swiss Institute of Bioinformatics, Switzerland

Government & Academic Research InstitutesLife Sciences Industry

Thomas Wilckens, Chief Executive Officer, CSO & Founder, InnVentis, Israel

James TimmonsCSOXRGenomics LTD., UKManuel HeuerChief Operating Officerdacadoo, Switzerland

Innovative Start-ups

Dr. Kerstin Bode-GreuelDir. Business Development & Marketing RWEIMS Health, GermanyDr. Rolf GüntherChief Information OfficerQlaym Healthcare, Germany

Dr. Alexander FrenzelSenior Manager, Business Development T&AIMS Health, Germany

Expert Solution Providers

Christine BienvenuFounderSuis(s)ePatiente, SwitzerlandPiers MahonDirector, Global AlliancesCancer Commons, UK

ePatients & Patient GroupsEric SteagerDirector - Corporate Development & Innovation Managing Director, Strategic Innovation PortfolioIndependence Blue Cross, USA

Payers

Aubrey de GreyChief Science OfficerSENS Research Foundation, USA

Alex Zhavoronkov, Co-founderInsilico Medicine, CSOThe Biogerontology Research Foundation, UK

John Quackenbush, Professor of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Director, Founder & Board Chair, Genospace, USA

Cross-industry experts

Paul GrundyChief Medical Officer & Director Healthcare TransformationIBM Healthcare and Life Sciences, USAMark DemesmaekerVice President, Scientific Analytics, PerkinElmer, Switzerland

Costas BekasPrincipal Research Staff Member, Manager, Foundations of Cognitive SolutionsIBM Research, SwitzerlandYury RozenmanDirector of Business Development, Qualcomm Life, USA

R&D HW/SW Developers

Event Over v iew“Big Data” in the life sciences sector is now a strategic opportunity for all researchers, and the benefits may soon be captured by all stakeholders and society. Capturing, storing, maintaining data flow, structuring messy data, and improving the analysis of information-rich processes can offer deep insights for life science researchers, particularly the discovery, clinical & late-phases.

Companies who can exploit Big Data and advanced analytics when developing new products will have the potential to improve the competitiveness, productivity & efficiency of R&D in order to better demonstrate clinical benefit and improved outcomes. Not only will researchers benefit from enhanced insights into richer data, but so will other internal stakeholders, physicians, insurers, regulators and the patient. The potential for a Big Data strategy to facilitate the anticipated era of personalised & precision medicine makes it an increasingly essential part of any life science R&D organisation. Researchers & informatics experts need to turn huge, unstructured volumes from disparate data sources into structured data that can be used for advanced analytics to improve R&D intelligence.

This 3 day forum is the “must attend” event for those senior decision-makers looking to make the shift towards a dedicated big data strategy and for those looking to improve their implementation of data-driven approaches to enhance R&D decision-making.

Day One – Strategic Developments in R&D Big DataWill feature several keynote presentations from C-Level thought leaders on big data in the R&D space and heads of major research institutions who are at the front-end of the big data challenge. They will be discussing the strategic drivers for big data and key implementation hurdles and considerations to facilitate innovation.

Day 2 - Stream 1: Discovery & Omics Data ExcellenceThis 1 day stream will focus on data driven approaches in the drug discovery process and how implementing a dedicated big data strategy for precision medicines and large “Omics” data volumes can achieve deep insights that enhance R&D decision making.

Day 2 - Stream 2: Clinical & Patient-Level Data ExcellenceThis 1 day stream will feature best practice case studies of designing, collecting & managing large sets of clinical stage data from experts in the field. Specific interest will be paid to selecting and using EDC technologies and will analyse working models of outsourcing, whilst retaining control over data quality. This stream will also feature examples of use of disruptive technologies to develop secure, patient-level data, as well as examples of strategic partnerships between the key industry players, academia and patient networks to achieve patient-centric health outcomes.

Day 3 - Stream A – R&D IT & BioinformaticsOne of the key barriers to achieving success in R&D from a dedicated Big Data strategy, is how to realise R&D potential with the technical capabilities and limitations of IT. The cost of data storage may be declining rapidly, allowing Big Data to become more realistic than ever, yet it is still immense. Being able to predict which IT investments into modern infrastructure, advanced software and high-level security, will achieve a ROI is extremely difficult, especially given the wealth of expensive technological options. This stream will analyse the IT possibilities of today, as well as take a peak into the near-future, and how informatics teams can facilitate R&D teams to maximize their insights into the data to increase the intelligence of the whole R&D organization. Technical, Informatics, ROI & infrastructure.

Day 3 - Stream B – Digital R&D Health CollaboarationsDigital health often represents the convergence of connected health, m-health, quantified-self, genomics, diagnostics, social media, electronic medical records and other exciting technologies and trends. Digital health is among the key phenomena driving transformation in the life science industry and the quest for achieving patient and stakeholder value. This significant paradigm shift within healthcare and the rise of the “e-patient,” is creating vast opportunities for life science innovators to achieve critical insights into patient needs, but many questions remain unanswered and the exact way forward is uncertain. The wealth of healthcare “big data” emanating from novel-yet-disparate sources, creates as many challenges as opportunities and developing analytics from the “data deluge” is difficult. Yet digital health is also fostering collaboration opportunities between the life science industry, the e-patient and the broader healthcare system, all who share the goal of improving the patient experience. The aim of this one day stream, is to allow every stakeholder group (from patients, to the life science industry, payers, physicians, as well as technology and data companies) to voice their opinion on future possible collaborations and especially, how to realise the immense opportunities to improve product innovation to enhance patient value.

Event Str ucture

DAY 1 (24th January) DAY 2 (25th January) DAY 3 (26th January)

STRATEGIC DEVELOPMENTS IN R&D

BIG DATA

STREAM ONE: DISCOVERY & OMICS DATA EXCELLENCE

STREAM A: R&D IT & BIOINFORMATICS

STREAM TwO: CLINICAL & PATIENT-LEVEL DATA

EXCELLENCE

STREAM B: DIGITAL R&D HEALTH

COLLABORATIONS

Who Will Benefit:Scientific Officers, Chief Information Officers, Chief Technology Officers, Knowledge & Data Management (Discovery, Clinical & Real-World Data), R&D Analytics, Informatics, R&D Innovation, External Alliances & Innovation, R&D Strategy.

Also: VPs Directors & Senior Managers involved in:

Stream 1: Drug Discovery, R&D, Lead Identification & Target Validation, Screening, Translational R&D, Genomics & Proteomics, Biomarker R&D, Senior Scientist, Biostatistics, Biometrics, Precision Medicine, Personalised Medicine, Computational Biology.

Stream 2: Clinical Development, Clinical Data Management, e-Clinical, Electronic Data Management, Health Economics & Outcomes Research, Real-World Evidence Generation, Late-Phase Research, Epidemiology, Drug safety & Pharmacovigilance, Medical Information.

Stream A: Information Technology & Services, R&D IT, IT Hardware & Infrastructure, Software, Database Management.

Stream B: eHealth, mHealth, Connected Health, Digital Health Solutions, Strategic Medical Innovation, Business Development, Strategic Collaborations, Alliances, External Innovation, Patient Engagement

Event Structure:

Event Partners:

08.00 Registration & Coffee08.30 Chairperson’s Opening Remarks: Dr. Kerstin Bode-Greuel Dir. Business Development & Marketing RWE IMS Health, Germany

LEVERAGING DATA INTELLIGENCE TO REDEFINE THE R&D MODEL IN LIFE SCIENCE

08.40 Transforming R&D innovation through pre-competitive collaboration

John Wise, Executive DirectorPistoia Alliance, UK

09.20 New innovation models for biopharmaceutical innovation: preparing the next generation of healthcare professionals

❖ Healthcare entering the era of precision medicine. ❖ Convergence of medicine, life sciences and physical sciences,

engineering and management. ❖ Emergence of translational medicine ❖ Healthcare providers, scientists, managers and policy makers need

knowledge and skills in translational medicine. ❖ Need for new education programs in translational medicine.

Prof. Michel Goldman, Institute for Interdisciplinary Innovation in healthcareUniversité Libre de Bruxelles, Belgium

10:00 Innovation to deliver a reform to enable to manage health of a population with data

Paul Grundy, Chief Medical Officer & Director Healthcare Transformation, IBM Healthcare and Life Sciences, USA

10.40 Networking & Coffee Session:

11:10 Rejuvenation Biotechnology: the sweet spot between prevention and treatment of age-related ill-health

❖ Areas for Pharma R&D to focus on to achieve advances in longevity.

Aubrey de Grey, Chief Science OfficerSENS Research Foundation, USA

11:40 Advancements in high performance computing, machine learning and artificial intelligence that can improve drug discovery and translational research

John Quackenbush, Professor of Biostatistics and Computational Biology, Dana-Farber Cancer InstituteDirector, Founder & Board ChairGenospace, USA

12:10 How Deep Data and Predictive Analytics can enhance R&D Portfolio Management

❖ Identify new patient target groups for innovative drug development by applying Predictive Analytics to real world and trial data.

❖ Enhance R&D productivity by mapping the real world using predictive analytics.

❖ Facilitate the implementation of Adaptive Pathways through Predictive Analytics.

Dr. Kerstin Bode-Greuel, Dir. Business Development & Marketing RWEIMS Health, Germany

Dr. Rolf Günther, Chief Information OfficerQlaym Healthcare, Germany

12:50 Luncheon Break

13:50 Industrializing the generation and broad secondary use of human exploratory data

Sandy FarmerExecutive Director, Enterprise Science & Technology OperationsPfizer Worldwide R&D, USA

BIG BIOMARKER DATA

14:20 Big Biomarker data as a means of selecting the most efficacious & safe treatment

Johan Luthman, VP Neuroscience Clinical DevelopmentEisai, USA

TECHNOLOGY AND ITS IMPACT ON CLINICAL RESEARCH AND RwE ANALYTICS

14:50 How will technology innovation change the way we perform clinical research

Barbara Voith, Head Global Clinical Sciences OperationsBayer AG, Germany

15.20 Networking & Coffee Session

15:50 Maximizing the value of Real World Evidence

Making best use of Real World Data depends on the ability to turn real world data into evidence into actionable insights and requires an efficient setup for data access or collection, management, wrangling (mapping, cross-walking , quality control), analytics, data visualization etc. Challenges and opportunities exist on several levels:

❖ Understanding and addressing specific needs of different data users or audiences to maximize usefulness of the data.

❖ Setting up the appropriate data infrastructure to handle many different and often large datasets.

❖ Ensuring proper governance since health data are typically sensitive or confidential.

Peter Speyer, Global Head of Real World Evidence SolutionsNovartis, Switzerland

16.20 Panel Discussion: Technological convergence redefining the future R&D models in life sciences

❖ Transition from sick-care to health-care and the technology convergence enabling this change.

❖ Technology and strategic approaches enabling the use of consumer & patient data in R&D.

❖ Internet of Things will have 50 billion objects by 2020, how to best leverage this connectivity?

❖ Harnessing the power of precision medicine and genomics through converging technologies.

John Wise, Executive Director, Pistoia Alliance, UKProf. Michel Goldman, Institute for Interdisciplinary Innovation in healthcareUniversité Libre de Bruxelles, BelgiumPaul Grundy, Chief Medical Officer & Director Healthcare Transformation, IBM Healthcare and Life Sciences, USA

Johan Luthman, VP Neuroscience Clinical Development, Eisai, USABarbara Voith, Head Global Clinical Sciences Operations, Bayer AG, GermanyPeter Speyer, Global Head of Real World Evidence SolutionsNovartis, Switzerland

Sandy FarmerExecutive Director, Enterprise Science & Technology OperationsPfizer Worldwide R&D, USA

17.10 Chairperson’s Closing Remarks 17.20 End of Day One

19:30 - Exclusive Complimentary Networking Dinner for all event participants

DAY 1 24th January 2017

STRATEGIC DEVELOPMENTS IN R&D BIG DATA

08.00 Registration & Coffee08.30 Chairperson’s Opening Remarks: Thomas Wilckens Chief Executive Officer, CSO & Founder, InnVentis, Israel

PRECISION MEDICINE

08.40 Harnessing the power of precision medicine and omics through converging technologies: Lessons from building a vertically integrated business model for scale

Thomas Wilckens, Chief Executive Officer, CSO & FounderInnVentis, Israel

09.20 Towards next-gen Precision Medicine: Role of diagnosis in the age of ‘big data’, and integration around the patient journey

❖ Towards a more collaborative innovation ecosystem, across silos.

❖ From single biomarkers to multi-modal biomarker models. ❖ Role of outcome-based feedback loops, from a biomarker

perspective. ❖ Regenerative medicine examples, related to chronic diseases.

Michael Rebhan, Senior InvestigatorNovartis Institutes for BioMedical Research, Switzerland

INTEGRATED ANALYSIS

10:00 Integrated data analysis of multi-omics data

❖ Overview of multimodal data integration and analysis: Connecting intermediate molecular phenotypes for meaningful inference of genotypes to phenotypes.

❖ Importance of network-based analytics in gaining biological insights into disease mechanisms.

❖ Combining imaging data with omics data for patient stratification and disease monitoring.

Chinnappa Kodira, Head of Bioinformatics, Diagnostics, Imaging and Biomedical Technologies, GE Global Research, USA

10.40 Networking & Coffee Session:

MACHINE LEARNING, BIG DATA & AI IN DRUG DISCOVERY

11.10 Applications of machine learning and big data in the context of expediting drug discovery

❖ Computational simulation for the evaluation of benefits and risks of therapeutic approaches.

❖ Scaled up Machine Learning approaches to learn and predict the biochemical impact of compounds based on their chemical structure or phenotypic effects, or the sensitivities to compounds dictated by a given genetic makeup of cancer cells.

❖ Multilateral collaboration example: Intel, the micro and nano-electronics research center Imec, Janssen and the five universities in Flanders, Belgium to found the ExaScience Life Lab, which states the creation of novel supercomputer solutions for applied life sciences as its mission.

Pieter Peeters, Senior Director, Computational Biology – Discovery SciencesJanssen, Belgium

11:50 Artificial intelligence for drug discovery, biomarker development and aging research

Alex Zhavoronkov, Co-founder, Insilico MedicineCSO, The Biogerontology Research Foundation, UK

12:30 Luncheon Break

USING BIG DATA TO BETTER DESIGN NEw MOLECULAR ENTITIES

13:30 Building a Systematic Immunophenotyping Data Collection and Analysis Strategy

❖ ‘Classic’ –omics data focus on a census of available ‘building blocs’.

❖ Rigorous immunophenotyping will be the first phenotypic data –omics.

❖ Technical and technological innovations allowing an immunophenotyping database build will be explained.

❖ A data analysis strategy taking into account the phenotypic nature of immunophenotyping will be discussed.

Anka G. Ehrhardt, Director Clinical Cytometry, CTTO, ECTRBMS, USA

14:10 Developments in multi-disease blood OMIC diagnostics for health surveillance

James Timmons, CSO, XRGenomics LTD., UK

14:50 Large-Scale Tumor Analytics for Deep Cancer Genomics Discovery

Very large collections of cancer genomic data allows us to see not just breadth of variation, but patterns in cancer formation and progression valuable to cancer research and drug development.

❖ One approach we are investigating allows the determination of the complete set of genomic structures within the cancer data based on advanced informatics algorithms.

❖ These structures can be analyzed and interpreted to discover mechanistic and oncogenic relations difficult to see with smaller cancer sets.

❖ In addition, the structures can be used as pre-computed input to a wide range of deeper data mining and modeling applications, aka Big Analytics.

❖ We see such transformation of collections of genomic data into these rich and re-usable information-derived structures as an important step forwards for genomic based cancer discovery.

Eric Neumann, VP of Knowledge Informatics, Foundation Medicine, USA

15.30 Networking & Coffee Session:HIGH-PERFORMANCE COMPUTING

15:50 The impact of high-performance computing on proteomics data analysis

❖ KiNativ – a proteomics platform broadly applicable to all phases of drug discovery and development.

❖ The challenge of high-volume, mass spectroscopy data analytics. ❖ Moving from conventional clusters to hybrid cloud/on-site HPC

resources.

Helge Weissig, Director, Bioinformatics, ActivX Biosciences, USA

16.30 Panel discussion: Prioritising unmet need medicines ❖ Next-generation sequencing, proteomic & genomic big data

– as a source of developing new biomarkers & personalised medicines – How do we deal with the data bottleneck?

❖ How can strategic collaborations advance data-driven drug discovery?

❖ Which advanced technological methods will be shaping the future of Big Data?

❖ What impact will high-performance computing have on drug discovery and translational science?

Michael Rebhan, Novartis Institutes for BioMedical Research, SwitzerlandChinnappa Kodira, GE Global Research, USAPieter Peeters, Janssen, BelgiumAlex Zhavoronkov, Insilico Medicine &The Biogerontology Research Foundation, UKAnka G. Ehrhardt, BMS, USA

17.10 Chairperson’s Closing Remarks 17.20 End of Day Two

DAY 2 - Stream One 25th January 2017

DISCOVERY & OMICS DATAEXCELLENCE

08.00 Registration & Coffee08.30 Chairperson’s Opening Remarks: Francis Crawley Executive Director, Good Clinical Practice Alliance – Europe, Belgium

TECHNOLOGY & STRATEGIC APPROACHES

08.40 Technological and strategic approaches enabling the use of consumer & patient data in R&D

Armin Furtwaengler, Global Senior Medical Director Respiratory; Global Team Leader Medical Affairs, Boehringer Ingelheim, Germany

09.10 Healthcare and pharmaceutical sector collaborations: Possibilities of taking advantage of EMRs to enhance pharmaceutical innovation for patient benefit

Dipak Kalra, President, EuroRec Institute, Professor, Health InformaticsUCL, UK

09:40 Implementing a central data review process in your CDM

Jan Breemans, Senior Director, Head Global Data ServicesGrunenthal, Belgium

10.10 Networking & Coffee Session:

RwE ANALYTICS & PREDICTIVE MODELING

10.40 RWE and its role in today’s Clinical development plans (CDP’s)

❖ How patient centered drug design can inform RWE needs. ❖ Using Structured benefit risk to aid design of controlled trials

and prospective RWE. ❖ The regulatory outlook for RWE.

John Glasspool, EVP, Head of Corporate Strategy and Customer OperationsBaxalta, USA11.10 RWE Information Lifecycle Management: Avoiding the merry-go-round

❖ All data has a lifecycle of its own and needs to be managed through the product lifecycle and across therapeutic areas.

❖ We need to develop virtual cohorts of both data and sample access for Discovery, Development and Deployment (commercialisation) of therapeutic agents.

❖ There are a number of opportunities and challenges to be addressed and use cases, such as IMI programmes will be explored.

Nigel Hughes, Scientific Director, RMEDS, Quantitative Sciences, Janssen, Belgium

11:40 Fallen Angels: Rescue your drug through Predictive Analytics applied to clinical trial data

Speaker TBC, IMS Health

12:20 Luncheon Break

13:30 Advanced analytics and visual decision support for better outcomes

❖ The current trend towards precision medicine and value-based treatment schemes has triggered a fundamental shift in the broader healthcare ecosystem.

❖ A new model of close cooperation between stakeholders is arising, leveraging clinical- as well as real-world data (RWD) to improve patient outcomes. Evidence around outcomes, in particular beyond randomized clinical trials, is becoming the new currency in healthcare – driving decisions and adding substantial value to a broad range of key steps along the Pharma & Medtech value chain, such as translational medicine, trial design & -recruitment, market access, pricing & reimbursement. PerkinElmer is currently collaborating with various partners on applying the flexibility of the TIBCO Spotfire analytics platform, paired with the new PerkinElmer Signals suite to build evidence around outcomes, allowing collaboration within and across the corporate firewalls to integrate data from disparate platforms.

Mark Demesmaeker, Vice President, Scientific Analytics,PerkinElmer, Switzerland

14:00 Coupling in-silico cardiac safety assessment to Real World Data outcomes

❖ Increasing emphasis moves towards the implementation of in-silico methods for offering an improved translation between in-vitro, in-vivo and clinical data.

❖ The focus for these in-silico cardiac models however is not just to predict single cell outcomes (e.g. action potential) or whole-body physiological outcomes (e.g. ECG), but instead to population-level outcomes(e.g. incidence of pro-arrhythmia).

❖ Careful consideration of what the ideal data set should be is therefore needed to ensure that those critical model validation exercises will result in the most predictive model for cardiac risk assessment.

❖ This presentation shall discuss these aspects and present work evaluating current in-silico tools for those candidate data sets.

Mark Davies, Modelling and Simulation Scientist, Roche, Switzerland

THE ROLE OF STRATIFIED REGISTRIES IN PRECISION MEDICINE

14:30 Stratified registries: revolutionising clinical research and uptake in precision medicine

❖ Precision medicine makes every disease a string of rare diseases. This makes conventional trials expensive and difficult to recruit. Clinical registries have been shown in rare disease to be the complimentary research tool to randomised trials. Traditionally, they have little molecular information, but they do have good clinical outcome data.

❖ This talk will look at how to repurpose Europe’s conventional cancer registries into stratified registries using generic molecular tests, and about the types of new discovery and translational innovation that such registries can then unlock, especially in less common cancer.

Piers Mahon, Director, Global Alliances, Cancer Commons, UK

15.00 Networking & Coffee Session:

DATA GOVERNANCE, PRIVACY & PROTECTION

15.30 Privacy and data protection – strategic considerations

❖ EU General Data Protection Regulation (GDPR) - blessing in disguise?

❖ Data privacy (big) data life cycle - what do you need to know? Human subject research and best use of available data.

❖ Patient Support Programs - what is feasible?

Hans Martens, Regional Privacy Manager Europe, GSK, Netherlands

16.00 Good data governance practices: Instituting policies on ethics, privacy, transparency and legal issues

Francis Crawley, Executive DirectorGood Clinical Practice Alliance – Europe, Belgium

16.30 Panel Discussion: Emerging technology and strategic approaches enabling the use of consumer & patient data in R&D

❖ Big data for clinical trials – data and technology driven clinical trials.

❖ Data visualization & analytics techniques for clinical trial insights. ❖ What challenges related to globalisation and digitisation of the

drug development and trial process are likely to have impact on future of data governance, data transparency and IP?

❖ Innovative application of new processes/technology in your CDM system.

❖ Contract negotiation & management & milestones for the Clinical Data Management context.

Armin Furtwaengler, Boehringer Ingelheim, GermanyDipak Kalra, UCL, UKNigel Hughes, Janssen, BelgiumPiers Mahon, Cancer Commons, UKHans Martens, Regional Privacy Manager Europe, GSK, NetherlandsJohn Glasspool, Baxalta, USA17.20 Chairperson’s Closing Remarks 17.30 End of Day Two

DAY 2 - Stream Two 25th January 2017

CLINICAL & PATIENT-LEVEL DATA EXCELLENCE

08.20 Registration & Coffee08.50 Chairperson’s Opening Remarks:

COGNITIVE COMPUTING

09.00 How will cognitive computing change R&D in life sciences

Costas Bekas, Principal Research Staff Member, Manager, Foundations of Cognitive SolutionsIBM Research, Switzerland

GENOME INFORMATICS PLATFORMS

09.40 The genome informatics platform enabling the path helix to healthcare

Nevenka Dimitrova, CTO Genomics, Healthcare IT, Philips Research, USA

TECHNOLOGIES AND APPLICATIONS FOR MANAGING AND SHARING DATA

10.20 Compute anywhere: Bringing high performance computing and computational biology to the data

❖ Moving large datasets, internal and public, is cumbersome and impractical.

❖ Moving patient-derived data might not be permitted due to regulatory restrictions.

❖ Therefore we require the paradigm shift of moving tools/applications to the data, wherever it might be located.

❖ Our approach to create arbitrary computed resources and supply the desired data for analysis for our scientists.

Henning Kuich, IT Project Manager for Early ResearchBayer, Germany

11.00 Networking & Coffee Session:

11.30 ELIXIR building a sustainable infrastructure for biomedical data in Europe

Torsten SchwedeProfessor, BioinformaticsBiozentrum University Basel & Swiss Institute of Bioinformatics, Switzerland

12:10 Increasing interoperability & secure sharing to data sources — particularly when conducting external collaborations

Mollie Shields UehlingPresident & CEOSAFE-BioPharma Association, USA

12:50 Luncheon Break

13:50 Making genomic and health data interoperable and sharable

❖ Current status and challenges of big genomic datasets, view of how many genomes will be sequenced in next few years.

❖ Consequences of not acting. ❖ Role of Global Alliance, mission and approach of the coalition,

organisational, global membership, active volunteer network. ❖ Software tools, standards and policies which have been

released and free to use by the community. ❖ Current demonstration projects which share genomic data and

the technical side of these (Beacon, Matchmaker Exchange, BRCA challenge, New cancer genomic data sharing initiative).

❖ Challenges and opportunities of linking genotype to phenotype and electronic health records.

Julia WilsonAssociate Director External RelationsWellcome Trust Sanger Institute & Global Alliance for Genomics and Health, UK

Stephen KeenanData and Security Working Group Manager for Global Alliance for Genomics and HealthEuropean Bioinformatics Institute, UK

FUTURE TALENT DEVELOPMENT

14.40 Educating the healthcare workforce - prepared for the genomic revolution?

❖ We have now entered the era of clinical genomics, no longer are we limited to studying single genes for genetic conditions but with the advent of genomic sequencing we can sequence whole exomes and now genomes from large numbers of individuals.

❖ In doing so, we are creating huge amounts of data; requiring a step change in how we analyse, interpret, store and share this information, all of which are a critical role of the Clinical Bioinformatician.

❖ This presentation will cover Manchester’s experience of educating healthcare professionals over the last 3 years in the areas of bioinformatics and genomics, our approach to multidisciplinary learning and also the development of our M.O.O.C.“Clinical Bioinformatics: Unlocking genomics in healthcare”, delivering education to 1000s of learners.

Ang Davies, Lecturer in Healthcare Sciences, Clinical Bioinformatics and Genomic Medicine Programme DirectorUniversity of Manchester, UK (TBC)

15:20 Panel Discussion: Implementing next-generation IT solutions to facilitate R&D

❖ Which IT platforms & analytics will soon become the industry standard to enable high-performing R&D organisations?

❖ Using Big Data analytics to enhance decision making. ❖ What impact will high-performance computing and Big Data

process have on future life science research? ❖ Slow adaptors of novel innovative technology solutions and the

dangers of not being up to date with technological progress.

Costas Bekas, Principal Research Staff Member, Manager, Foundations of Cognitive SolutionsIBM Research, Switzerland

Nevenka Dimitrova, CTO Genomics, Healthcare IT, Philips Research, USA

Henning Kuich, IT Project Manager for Early ResearchBayer, Germany

Torsten Schwede, Professor, Bioinformatics, Biozentrum University Basel & Swiss Institute of Bioinformatics, Switzerland

Mollie Shields Uehling, President & CEOSAFE-BioPharma Association, USA

Stephen Keenan, Data and Security Working Group Manager for Global Alliance for Genomics and Health, European Bioinformatics Institute, UK

Ang Davies, Lecturer in Healthcare Sciences, Clinical Bioinformatics and Genomic Medicine Programme DirectorUniversity of Manchester, UK (TBC)

16.00 Chairperson’s Closing Remarks16.10 End of Day Three

DAY 3 - Stream A: 26th January 2017

R&D IT & BIOINFORMATICS

08.20 Registration & Coffee08.50 Chairperson’s Opening Remarks:

FUTURE TRENDS IN DIGITAL HEALTH 09.00 Digital Health: Shifting the focus of care to patient experience

❖ Sanofi, example on development and use of mobile health (mHealth) technologies to empower patients to self-manage their diseases.

❖ Use of mHealth technologies are being explored as a new strategy for osteoarthritis (OA) management. mHealth technologies allow for tailored and comprehensive disease self-management by providing continuous, real-time feedback to patients (physical activity progress, motivational messages and reminders). Sanofi conducted a study to examine the potential of mHealth technologies to improve mobility of patients with OA of the knee.

Svetlana Pidasheva, Director, Scientific Communications and Publications Established Products and Emerging Markets, Sanofi Biosurgery, USA

09.30 Connected, Continuous & Coordinated: How mHealth improves standards of care and enables connected therapies in order to improve therapies and outcomes

Yury Rozenman, Director of Business Development, Qualcomm Life, USA09.50 Healthcare IT innovations that are connecting patients, providers & payers: Connected health

Eric Steager, Director - Corporate Development & Innovation Managing Director, Strategic Innovation Portfolio, Independence Blue Cross, USA10.10 Digital Health Collaborations: Google & Alcon project

Simone Breitkopf, Head Governmental and Public Affairs Pricing and Reimbursement, Alcon Laboratories, Germany10:30 Panel Discussion: Digital Health: Shifting the focus of care to patient experience

❖ Connecting the dots and creating closed loop systems to help profoundly transform the healthcare.

❖ Healthcare IT innovations that are connecting patients, providers & payers: Connected health.

Svetlana Pidasheva, Sanofi Biosurgery, USAYury Rozenman, Qualcomm Life, USAEric Steager, Independence Blue Cross, USASimone Breitkopf, Alcon Laboratories, Germany11.00 Networking & Coffee Session:

PATIENTS AND THEIR ROLE IN DIGITAL HEALTH COLLABORATIONS

11.30 Partnering with a growing community of empowered ePatients

❖ Empowered patients are now speaking up. ❖ ePatient culture awareness ❖ How could patients and the industry work together? ❖ Partnering with patients to build strategies that are compelling

to regulators and payers.Christine Bienvenu, Founder, Suis(s)ePatiente, Switzerland11.50 Leading Patient Engagements: From patient data analytics to mHealth interventions

Dr. Alexander Frenzel, Senior Manager, Business Development T&A, IMS Health, Germany12:10 Digital Health Collaborations: Mylan and the Sheffield Institute for Translational Neuroscience (SITrAN) team up to provide digital services to patients living with ALS.

❖ Use of patient reported outcomes to help reduce unnecessary scheduled visits.

❖ Data visualization for the health care providers to help them understand the patient data quickly.

❖ Clinical validation of the apps and lessons learned. David Heard, Head of Digital Health, Mylan, Switzerland

12:30 Panel Discussion: Tailoring future solutions to patient needs ❖ What do patients expect from the industry. ❖ How can industry benefit from working closely with patients. ❖ Convenience vs. Privacy in Consumer Health Apps.

Christine Bienvenu, Suis(s)ePatiente, SwitzerlandDr. Alexander Frenzel, IMS Health, GermanyDavid Heard, Mylan EPD, Switzerland

13:00 Luncheon BreakwEARABLES AND BIOSENSORS & THE FUTURE OF

HEALTHCARE14.00 What impact will the explosion in wearable and biosensors technologies have on health and fitness services?

❖ Market data on the current trends and developments in digital health and wearables industry to demonstrate how wearables are a driver of growth in the digitalization process of health services.

❖ Reducing the difference between a medically approved wearable and a normal consumer wearable.

❖ Strategic move from “active” tracking towards “passive” tracking, where the user won’t need to do anything anymore to capture his/her lifestyle.

❖ With the addition of real-time and near real-time data on health and fitness, one can provide relevant, context-based personalized feedback and coaching to the individual, making health services much more relevant today.

❖ Applications in the industry.Manuel Heuer, Chief Operating Officer, dacadoo, Switzerland

14.30 Digital Health Measures for Neurodegeneration

❖ Opportunities and challenges in applying digital health to neurodegeneration.

❖ From fitness tracking to clinical benchmarking and outcome measures.

❖ Beyond wearables and movement sensing.Hank Wu, Director, Digital Strategy & Innovation | Digital Health Tech & Data Sciences, Biogen, USA

STRATEGIC R&D COLLABORATIONS14.50 Who’s Your Daddy? How to (and not to) build a start-up within a behemoth: The Case of SHIELD

❖ SHIELD (Skin Health Investigation, Education, Longevity Development) is a global collective of ten innovation hubs creating and advancing scientific, cultural and technological ideas in skin health and longevity.

❖ Creating and maneuvering a digital health start-up within the confines of a large, traditionally structured corporation poses significant cultural and operational challenges.

❖ This talk will review how SHIELD’s disruptive approach achieved early successes internally at Nestle Skin Health, S.A. and externally throughout the New York City digital health ecosystem.

Warren Winkelman, Senior Medical Director and Head of Medical Innovation, Nestlé Skin Health (SHIELD), USA15:10 Panel Discussion: Strategic digital R&D collaborations

❖ What shape will future cross-industry collaborations have? ❖ What impact will engaging external have on R&D innovation?

Hank Wu, Biogen, USAWarren Winkelman, Senior Medical Director and Head of Medical Innovation, Nestlé Skin Health (SHIELD), USAManuel Heuer, dacadoo, SwitzerlandYury Rozenman, Director of Business Development, Qualcomm Life, USAEric Steager, Director - Corporate Development & Innovation Managing Director, Strategic Innovation Portfolio, Independence Blue Cross, USA15.50 Chairperson’s Closing Remarks16.00 End of Day Three

DAY 3 - Stream B: 26th January 2017

DIGITAL R&D HEALTH COLLABORATIONS

Event Par tner s

Are you interested in presenting your company products and services to this senior-level audience? If so please contact: sponsorship@nextlevelpharma.com Our team will be happy to tailor a package to suit your needs and get you the optimal level of exposure!

Event Partners:

& Networ k ing

Networking - Join the industry’s best, most intimate events for networking!The Life Science R&D Data Intelligence Leaders Forum will provide all delegates the chance to meet one another through our many networking opportunities. With mid-morning and mid-afternoon breaks as a standard, this event will also feature a complimentary networking dinner for all participants. This evening will allow you to meet with our expert speaker panel who represent many stakeholder groups in a less formal setting. Our networking lunches will also allow you plenty of time to meet with your peers and colleagues whilst you refuel through the event.

Media Partners:

Company Job Title Country

ResMed Germany Inc VP Clinical Research and Medical Director EMEA / A

Germany

Aspera, an IBM Company Marketing Manager EMEA United Kingdom

Aspera, an IBM Company Regional Manager Sales Engineering EMEA

United Kingdom

Aspera, an IBM Company Senior Sales System Engineer United Kingdom

Aspera, an IBM Company Sales Director UK & Ireland United Kingdom

Nestlé Research Center Biostatistician Switzerland

Abbott Vascular Director, Clinical Research United States of America

INVISTA Textiles UK Ltd R&D Director United Kingdom

INVISTA Textiles UK Ltd Research Scientist II United Kingdom

Illumina Vice President Software Engineering United States of America

InnVentis Chief Executive Officer, CSO & Founder Germany

MSD Associate Vice President and Head Structural Chemistry

United States of America

Insilico Medicine Co Founder United States of America

Healx CSO United Kingdom

Astrazeneca Executive Director & Head, Advanced Analytics Centre

United Kingdom

PatientsLikeMe Vice President of Innovation United Kingdom

Merck Research Labs Senior Vice President Global Clinical Development

United States of America

Philips Research Research Fellow, Senior Director Clinical Informatics Solutions and Services (CISS)

United States of America

BERG Vice President of Systems Medicine United States of America

ActivX Chairman & President United States of America

GSK Director, Computational Biology United Kingdom

Roche Pharmaceuticals Principal Scientist Switzerland

Apceth Chief Scientific Officer Germany

Pfizer Computational Scientist United Kingdom

The University of North Carolina, Eshelman School of Pharmacy

Professor, Center for Integrative Chemical Biology and Drug Discovery

United States of America

4-Antibody AG Senior Director, Bioinformatics Switzerland

Biogen Idec Senior Scientist, Computational Chemistry United States of America

Bayer Postdoc in bioinformatics (translational research, eTRIKs)

Germany

Novartis Value Evidence Leader, Outcomes Oncology

United Kingdom

UCB Senior Director – Head of Information Intelligence and Integrity

Belgium

AliveCor EU General Manager United Kingdom

The Michael J. Fox Foundation for Parkinson’s Research

Director of Data Science United States of America

SAFE-BioPharma Association

President & CEO United States of America

GSK Regional Privacy Manager Europe Netherlands

Bayer Business Services Head of CropScience Research IT Germany

Genentech Scientist - Early Stage Pharmaceutical Development

United States of America

Curoverse Director of Informatics United States of America

European Commission Project Manager - EUDAT, E-Infrastructure Belgium

Bayer Business Services IT Portfolio manager Germany

Structural Genomics Consortium

Principal Investigator of Research Informatics

United Kingdom

In-Silico Biosciences Chief Operating Officer United States of America

Centre for Molecular Informatics, Cambridge University

Lecturer for Molecular Informatics, Chemistry

United Kingdom

UCB Director,Innovation Super Networks United States of America

University of Cambridge Prof Emeritus, Surgical Oncology United Kingdom

Company Job Title Country

F. Hoffmann-La Roche AG

Program Manager Integrated Cancer Care Unit

Switzerland

Roche Diagnostics GmbH Head of Clinical Information Management Germany

UCB Clinical Program Director Germany

Sanofi Vice President, Global Head United States of America

Boehringer Ingelheim Pharma GmbH & Co KG

Head of Licensing & Consortia in TA Respiratory

Germany

Boehringer Ingelheim Pharma GmbH & Co KG

Head of IT Epidemiology Germany

AstraZeneca VP R&D Information United Kingdom

Novo Nordisk A/S Senior Strategy Manager Denmark

Novo Nordisk A/S Manager Denmark

Novo Nordisk A/S CVP Partner | Interim Head of GRI Denmark

Servier Data and Clinical Logistics Director France

Servier ISD Project Manager Clinical Development France

Ipsen Pharma Director Bioinformatics France

Bayer Business Services GmbH

Head of Biology system Germany

Philips Research Department Head Data Science Netherlands

Philips Research Concept Business Architect Netherlands

Astrazeneca Head of Early Clinical Development United Kingdom

Adamed Sp. z o.o President - Adamed Group Poland

Roche Senior Programmer Analyst United States of America

ActivX Biosciences, Inc. Director, Bioinformatics & IT United States of America

UCB Data Intelligence Manager, Information Intelligence

Belgium

Bayer Director and Global TA Head Epidemiology Germany

Roche Developer Poland

The Genome Analysis Centre

Head of Scientific Computing United Kingdom

Bayer Director Global Epidemiology Germany

Bayer Pharma AG Head of IT Architecture and Processes Germany

Lundbeck Lead Project Director Denmark

Novo Nordisk A/S Principal Data Management Denmark

Almirall R&D BT Partner Spain

Almirall Information Management Manager Spain

Nestlé Institute of Health Sciences

Systems Biology Expert Switzerland

Genedata Business Development Switzerland

Proteome Sciences R&D Group Leader Bioinformatics Germany

Ipsen Big Data & Analytics director France

Roche Diagnostics GmbH Head Scientific & Business Information Services

Germany

Aspera, an IBM Company Account Manager UK & Ireland United Kingdom

Elsevier VP Strategy and Business Development, Life Sciences

United States of America

Open PHACTS Foundation

CEO United Kingdom

Arvados Project Co-founder United States of America

Anovative s.r.o. CEO Slovakia

SAP Solution Manager for Life Sciences Germany

inhive Group Specialist, Bioinformatics & Comp. Bio Switzerland

Roche IT Program Manager Switzerland

Bayer Vital GmbH Clinical Data Process Technology Specialist

Germany

Bayer Pharma AG Business Partner Clinical Sciences Germany

Bayer Pharma AG Data Insights & Visualization Expert Germany

Elsevier Managing Director United States of America

Roche IT Program Manager Switzerland

Previous Attendees at Lifescience R&D Big Data Leaders Forum - London February, 2016

Speaker B iogr aph iesAubrey de Grey, Chief Science OfficerSENS Research Foundation, USA

Dr. Aubrey de Grey is a biomedical gerontologist based in Cambridge, UK and Mountain View, California, USA, and is the Chief Science Officer

of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the accumulating and eventually pathogenic molecular and cellular side-effects of metabolism (“damage”) that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

Barbara Voith, Head Global Clinical Sciences OperationsBayer AG, Germany

Pharmacist by education, PhD in Clinical Pharmacology, Clinical Pharmacokineticist by training with background in NCA as well as PK/PD modelling. With Bayer since 20 years, huge background in Pharma R&D, early as well as late stage, broad coverage of indications (CV, Oncology, Antiinfectives, Lung diseases, CNS, WH). Currently heading a global team of >100 people (US, EU, ASIA) with responsibility of operational execution on study and project level for early clinical studies – starting from FIH until POC – as well as all clinical pharmacology studies, experienced in conduct of healthy volunteer as well as patient phase IIa studies, esp. experimental study designs, covering study planning and conduct as well as medical writing, BM/PK sampling and assay validation, resource and process mgmt.

Julia Wilson, Associate Director External RelationsWellcome Trust Sanger Institute & Global Alliance for Genomics and Health, UK

Julia Wilson builds and supports the relationships that are needed to support the strategic vision of the Institute. These activities range from interactions with the scientific community, commercial entities, funders and other key stakeholders. Previously Julia was Assistant Director of Research at Breakthrough Breast Cancer and Science Programme Manager at the World Cancer Research Fund. As a scientist she was a post-doc at the Karolinska Institute in Sweden and then worked for a number of years at Cancer Research UK, first at LRI then at Barts Cancer Institute.

Christine BienvenuFounderSuis(s)ePatiente, Switzerland

Christine Bienvenu is a three-time (TNBC and HER2+) breast cancer survivor ePatient, based in Morges/Lausanne. Her ePatient

journey began in 2008, when North American online patient communities helped her learn about her son’s Asperger’s Syndrome. Inspired, she created Aspie Romandie, an “Aspies”-dedicated Facebook community in Western Switzerland (280+ members today). Diagnosed with breast cancer in 2010, Christine realised that no platforms or online communities existed for the Swiss French-speaking community. Determined, she became certified in Social Media. Her thesis work led, in 2012, to the creation of an online community and platform dedicated to those affected by breast cancer. Today, Seinplement Romand(e)s offers information and support (Blog, Facebook, Twitter) to 300+ members. A Board Member for the European Patient Empowerment Foundation, Christine teaches ePatient culture and social media use in healthcare at local clinics and university hospitals, and regularly speaks at national and international events on eHealth, ePatient culture, and patient empowerment.

Chinnappa KodiraHead of Bioinformatics, Diagnostics, Imaging and Biomedical TechnologiesGE Global Research, USA

Chinnappa Kodira is the Head of Bioinformatics at GE Global Research. Since joining the GE Research in 2012, Chinnappa has been leading GE’s collaborative initiatives in the area of precision medicine and computational modeling. A graduate of the Indiana State University, Chinnappa previously served in several leadership roles at some of the world’s leading academic and industrial centers including Roche 454 R&D, Broad Institute of MIT & Harvard, Celera Genomics, NCGR and UTMB. Before joining GE’s research team, he was the Director of Genomics and Bioinformatics at Roche 454 [2008-12] where he was responsible for NGS technology and tool development. As the Director of Genome Analysis at the Broad Institute of MIT and Harvard [2002-08], he led the bioinformatics efforts to support data analysis for several high-profile genomics initiatives including the Human Genome and Human Microbiome projects. He played a key leadership role in the genome annotation of the first sequenced Drosophila and human genomes at Celera Genomics (1999-2002]. He has coauthored more than 35 papers in peer-reviewed journals such as Nature and Science. He spent early part his career at the National Center for Genome Resources and the University of Texas Medical Branch.

Dipak KalraPresident, EuroRec InstituteProfessor, Health Informatics, UCL, UKDipak Kalra, PhD, FRCGP, FBCS, British, is President of the European Institute for Health Records (EuroRec) and of the European Institute

for Innovation through Health Data (i~HD). He plays a leading international role in research and development of electronic health record architectures and systems, including the requirements and models needed to ensure the robust long-term preservation of clinical meaning and protection of privacy. He leads the development of CEN and ISO standards on EHR interoperability, personal health records, EHR requirements, and has contributed to several EHR security and confidentiality standards. Dipak is involved in European research on EHR system quality labelling, semantic interoperability and clinical knowledge discovery. Dipak leads the Managing Entity (EuroRec) for a €16m Innovative Medicines Initiative on the re-use of electronic health record information for clinical research, EHR4CR, alongside ten global pharmaceutical companies. EuroRec is also a partner in another IMI project, EMIF, on the development of a European clinical research platform federating multiple population health and cohort studies. Dipak also leads an EU Network of Excellence on semantic interoperability, and is a partner in other EU projects on the sustainability of interoperability assets and the transatlantic sharing patient summaries. Dipak is Clinical Professor of Health Informatics at University College London, United Kingdom, a Director of the openEHR Foundation, and a member of standards bodies including CEN, ISO and HL7-UK.

David HeardHead of Digital HealthMylan, SwitzerlandDavid is an experienced wet lab Biologist turned Bioinformatician with extensive industry experience in different roles and organizations and

who is now designing and building new business opportunities around patient services for Mylan. His goal is to help improve patient outcomes, increase efficiencies and reduce costs of health care by helping patients communicate with health care providers, improve medication adherence/compliance and monitor themselves using cutting edge web-enabled devices.

Eric SteagerDirector - Corporate Development & Innovation Managing Director, Strategic Innovation PortfolioIndependence Blue Cross, USAMr. Steager is a Director of Corporate Development & Innovation and

Managing Director, Strategic Innovation Portfolio for Independence Blue Cross, focused on the identification, analysis and execution of strategic equity investments, as well as mergers and acquisitions. He is also an Adjunct Professor of Finance and Entrepreneurship at Drexel University. Prior to joining IBC, he spent four years at a private investment firm focused on venture capital and private equity investments, as well as three years at Safeguard Scientifics, a publicly traded venture capital firm. Prior to Safeguard, Mr. Steager’s career included founding a private investment fund focused on acquiring middle market manufacturing companies in the Midwestern United States, and healthcare investment banking at Houlihan Lokey and Ernst & Young. Mr. Steager holds a bachelor’s degree from Drexel University and an MBA with honors from the University of Chicago, Booth School of Business.

Svetlana PidashevaDirector, Scientific Communications and Publications Established Products and Emerging MarketsSanofi Biosurgery, USADr Svetlana Pidasheva is Director, Scientific Communications and

Publications at Sanofi. She joined Sanofi from Allergan where she was in charge of global medical publications for plastic surgery and medical dermatology. Prior Allergan, she was Assistant Medical Director at the Omnicom Group responsible for partnering with top pharma and biotech companies to develop scientific strategy and medical communication across multiple therapeutic areas. She also spent four years at Genentech/Roche focusing mostly on identification and characterization of potential biomarkers for inflammatory and autoimmune disorders in R&D. She got her PhD in Experimental Medicine from McGill University and co-authored 7 peer reviewed publications. Svetlana’s key areas of interest are: mobile health (mHealth) technologies, digital medical communications, social media and KOL engagement. Currently, she is in charge of scientific communications and publications for established products and emerging markets.

Yury RozenmanDirector of Business DevelopmentQualcomm Life, USAYury Rozenman currently leads pharmaceutical business development organization at Qualcomm Life. Prior to joining Qualcomm Life, Yury

was the head of healthcare and life sciences industry at BT Global Services where he was responsible for the development of life sciences vertical solutions, marketing programs, sales strategy and execution on the global basis. In addition Yury was responsible for driving strategic innovations, ensuring creative excellence and leading the R&D of emerging technologies in order to protect and grow market share for a multi-billion dollar product portfolio. Previous to this, Yury lead the pharmaceutical solutions practice for IBM Life Sciences working with top global pharmaceutical companies to develop and deliver solutions for R&D and Commercial operations. Yury has considerable experience working in and consulting to the pharmaceutical industry, strategic studies, new product and business development and manufacturing across the healthcare industry. Yury has over twenty years’ experience in pharmaceutical research and development both as a project team leader and group research manager. He has also worked in diagnostics and medical devices, and has been involved in the development and launch of world class drugs and diagnostic tests.

Speaker B iogr aph iesHank WuDirector, Digital Strategy & Innovation | Digital Health Tech & Data SciencesBiogen, USA

Hank is Director of Digital Strategy & Innovation at Biogen. His role includes strategic initiatives in digital health, public private partnership and innovation, and establishing Biogen as a destination for emerging tech talent. Prior to Biogen, Hank wrestled big data at The Institute for Genomic Research, ran computing at the U.S. National Lab for Cancer Research, and created software products at a Silicon Valley digital health startup. Hank earned his MS/MBA in Biotechnology at The Johns Hopkins University and BS in Electrical Engineering & Computer Science from the University of California at Berkeley.

Anka G. EhrhardtDirector Clinical Cytometry, CTTO, ECTRBMS, USA

Dr. Anka G. Ehrhardt is a biophysicist with a doctorate degree in human physiology. She is currently working in the United States for Bristol-Myers Squibb. Already during her academic career, Dr. Ehrhardt successfully developed technology and technology based methods, such as anisotropy detection based imaging. Later, she headed a technology laboratory at Merck, covering comprehensive instrumentation in high tech fields such as fluorescence, imaging, flow cytometry, electrophysiology and luminescence for the entire range from early discovery to late stage clinical trials across all disease areas. In her current position at BMS, Dr. Ehrhardt directs the Clinical Cytometry team, covering a large portfolio of immunology, immuno-oncology, and other disease area clinical studies. Her work focuses on the practicalities of biomarkers as tools to drive the development of urgently needed new medicines. This reaches form securing that biomarker assays are optimized to gather clear data in support of fast well founded decision making to systematically maximizing the information gathered from clinical samples to support hypothesis generation. Dr. Ehrhardt is currently on the board of different industry organizations, fostering innovation and collaboration between industry, academia and government organizations.

Alex Zhavoronkov, Co-founderInsilico Medicine, CSOThe Biogerontology Research Foundation, UK

Alex Zhavoronkov, PhD, is the CEO of Insilico Medicine, Inc (Baltimore, MD) and the CSO of the Biogerontology Research Foundation (Oxford, UK). The company is focusing on applying deep learning and advanced signaling pathway activation analysis to biomarker discovery, drug discovery and drug repurposing for aging and age-related diseases. He is the author of over 70 research papers and books including”The Ageless Generation: How advances in biomedicine will transform the global economy” (Palgrave Macmillan, 2013). Prior to switching his focus to aging research in 2004, he served as the director of Central and Eastern Europe at ATI Technologies, publicly-traded GPU company and the Chief Thought Architect at NeuroG, a neuroinformatics company. He holds two Bachelor degrees from Queen’ s University, a Masters in biotechnology from Johns Hopkins University, and a PhD in biophysics from the Moscow State University.

Eric NeumannVP of Knowledge InformaticsFoundation Medicine, USA

Dr Eric Neumann is Vice President of Knowledge Informatics at Foundation Medicine, responsible for organizing FMI’s knowledge assets and supporting knowledge discovery initiatives. He is a recognized world expert in semantic information and data modeling for the life sciences, and has worked on many information initiatives for the pharmaceutical and life sciences, including the W3C Semantic Web Healthcare and Life Science Interest Group (HCLSIG), BioPAX, and OMG Life Sciences. Dr Neumann has co-founded several companies, including Selventa, Clinical Semantics and Pangenx, and has been a consultant to several pharmaceutical companies to enhance their management of scientific and pharmacological information. Dr Neumann was also the Global Head of Knowledge Management for Scientific and Medical Affairs within Sanofi-Aventis, overseeing the reuse of knowledge and insights across a multinational company. Prior to that, he was VP of Informatics at Beyond Genomics, and systems biology company. Dr Neumann is a graduate of MIT and holds a PhD in neurobiology, developmental genetics, and pharmacology from Case Western Reserve University.

Manuel HeuerChief Operating Officerdacadoo, Switzerland

Manuel joined dacadoo in 2011 as COO, signing responsible for sales, marketing and operations. From 2003 to 2011, Mr. Heuer worked in various sales, business development & marketing roles with increasing management responsibilities in the medtech industry, first with Guidant Corp. in Belgium, France and Switzerland and then with St. Jude Medical as Managing Director of Switzerland from 2008 to 2011. From 1997 to 2001, Mr. Heuer held sales and marketing positions in the fast moving consumer goods industry with Nestlé in Brazil. Manuel Heuer holds an MBA from IMD International.

Michael RebhanSenior InvestigatorNovartis Institutes for BioMedical Research, Switzerland

Dr. Michael Rebhan (Ph.D.) is a scientist leading interdisciplinary, applied research related to human disease, with experience in fields such as biology, bioinformatics, disease profiling, clinical research, omics technology, disease mechanisms, and biomarker discovery. He spends much of his time building highly diverse, interdisciplinary teams in pioneering projects, to answer Translational Research questions on human disease. As Senior Investigator at the “Novartis Institutes for BioMedical Research” in Basel (Switzerland, 2008 - now), he focuses on addressing non-Oncology Precision Medicine challenges, in particular biomarker discovery and patient stratification, and complementary projects that aim to bring human disease data (gathered under real world conditions) back to R&D, in a way that is focused on specific medical need in defined patient populations. Increasingly, this involves a variety of human data trails, and in particular the analysis of temporal, multichannel data as they inform our understanding of disease progression and ‘disease states’ (as a basis for data aggregation). Enabling better integration around the patient journey, in the ‘new ecosystem’, is a long-term interest. This revolves around biomarker-based decisions in healthcare and R&D, as well as feedback loops for biomarker-based decisions based on outcome tracking in real world settings. His disease biology focus is on Regenerative Medicine, multifactorial diseases, and related medical problems (e.g. complications of chronic diseases). --- After a Masters in biology (1993), he did a PhD (1996) investigating fundamental aspects of disease progression and biology at a molecular, cellular and anatomical level, before doing a postdoc in ‘bioinformatics for the age of omics profiling’ (developing the first versions of GeneCards) at the Weizmann Institute (1996-1998). Before coming to Basel in 2004, he worked on building such capabilities in Singapore (A*STAR, Biopolis, Bioinformatics Institute, 2002-2004), Boston (AstraZeneca R&D center, 1998-2000) and other places (a biotech startup in Germany, 2000-2002). This includes some exposure to complementary fields like usability, system engineering, IT, pharma R&D, genomics/proteomics, biomedical big data infrastructures, drug discovery problems, community building, and business development. In 2004 he moved to Switzerland, and has stayed there since, to first join the FMI in Basel (to build up bioinformatics capability), before he joined NIBR Basel in 2008.

Ang DaviesLecturer in Healthcare Sciences, Clinical Bioinformatics and Genomic Medicine Programme DirectorUniversity of Manchester, UK

Ang Davies graduated with a BSc in Biochemistry from the University of Bath, before completing a PhD in Molecular Biology at the University of Warwick. From here she completed a postdoctoral research fellowship at AstraZeneca designing a high-throughput method for the expression and purification of proteins in mammalian cells. Later she moved to Renovo in Manchester as Principal Scientist within the Bioanalytics Department within drug development, there she was responsible for the analytical testing of drugs prior to their use in clinical trials. From 2010-14she managed the Education and Training Team at Nowgen, a partnership between Central Manchester University Hospitals NHS Foundation Trust and The University of Manchester. During this time she was responsible for overseeing their training programme and designing many new training programmes in particular in the areas of stratified medicine and next generation sequencing. Ang is Programme Director of two masters programmes in Clinical Bioinformatics and Genomic Medicine, both contracted by Health Education England. These programmes provide education to develop the UK healthcare workforce in order to realise the benefits to patients of initiatives such as the 100,000 genomes project. She also has an interest in the development of pedagogy in these areas and in particular Co-Lead the development and delivery of a massive online open course (MOOC) in Clinical Bioinformatics. She also has a leadership role in her Faculty for developing continuing professional development (CPD) for healthcare and the biotech sector.

Henning KuichIT Project Manager for Early ResearchBayer, Germany

Henning Kuich is a project manager in the R&D IT-OMICS group at Bayer Business Services. As a former wet lab scientist with a B.S. in Computer Science and a PhD in Biochemistry, he has spent his research years in epigenetics at the University of Virginia, as well as proteomics and metabolomics at the Max-Delbrück Center for Molecular Medicine in Berlin. With his strong focus on working at the intersection of biology and computer science, he has been involved in the development of GC-MS-based metabolomics methods and created software for the processing and analysis of the resulting data. Since arriving at Bayer in September 2015, he has been involved in bioinformatics application development as well as the establishment of high performance/data science IT infrastructure.

Dr. Sandy FarmerExecutive Director, Enterprise Science & Technology OperationsPfizer Worldwide R&D, USA

Since joining Pfizer in December 2014, Dr. Farmer has held the position of Executive Director in the Enterprise Science & Technology Operations department. During this time, he has focused on advancing and implementing a Big Data strategy in WRD; on developing a scientifically focused Biospecimen Management strategy and plan; and on building out the Precision Medicine framework that will enable researchers to develop data-driven insights that impact new target identification, target validation, and patient stratification across all therapeutic areas. From 2011-2014, Dr. Farmer held the position of Global Head, Scientific Information Management Expert Center within the global IT organization at Boehringer Ingelheim. In this role, he led a team of senior IT professionals responsible for developing and then advancing a global IT strategy around Scientific Information Management that provided for information access, mining, navigation, visualization, analysis and collaborative exchange across BI worldwide. Prior to 2011, Dr. Farmer had been involved in Drug Discovery for over 20 years, first with Bristol-Myers Squibb and then with Boehringer Ingelheim. He is a recognized Research leader and scientific expert in Structural Biology, Fragment-based Lead Discovery, and small-molecule drug design, and has extensive international experience in scouting out and integrating new computational and experimental technologies to advance drug discovery.

Speaker B iogr aph iesProf. Michel GoldmanInstitute for Interdisciplinary Innovation in healthcareUniversité Libre de Bruxelles, Belgium

From 1990 to 2008, Michel Goldman was the Head of the Department of Immunology-Hematology-Transfusion at the Erasme Hospital of the Université Libre de Bruxelles (ULB), and from 2005 to 2009 he served as the first Director of the Institute for Medical Immunology at ULB, funded through a public-private partnership with GSK vaccines. From 2009 to 2014, Michel Goldman was the first Executive Director of the Innovative Medicines Initiative Joint Undertaking (IMI). With a budget of 2 billion € provided jointly by the European Federation of Pharmaceutical Industries and Associations and the European Commission, he was responsible for 59 public-private consortia in areas of major importance, including antimicrobial resistance, Alzheimer’s dementia, autism, diabetes, immuno-inflammatory disorders, chronic pulmonary diseases and drug safety. In 2016, Michel Goldman created the ULB Institute for Interdisciplinary Innovation in Healthcare (I3h) to foster research, education and outreach networks for the benefit of patients and other stakeholders. The education program of the I3h Institute is supported by the Baillet-Latour Fund. Michel Goldman is also Full Professor in Immunology and Pharmacotherapy at ULB. Furthermore, he serves as the Chairman of the Scientific Committee of Effimune S.A. (French biotechnology company), is a member of the Board of Directors of CQDM (Canadian consortium for precompetitive research), and serves on the Strategic and Scientific Advisory Board of Genome Quebec. He also serves as the Editor-in-Chief of Frontiers in Medicine.Michel Goldman’s scientific achievements resulted in more than 400 articles in peer-reviewed journals and he was recognised as ISI Highly Cited Scientist in 2006 by the Thomson Institute for Scientific Information. In 1992, he received the Medical Prize Lucien Steinberg (shared with Pr. Peter Piot) and in 2000 the Quinquiennal Prize of the Belgian National Fund of Scientific Research for Clinical Sciences. He held in 2001 the Spinoza chair at the University of Amsterdam, the Netherlands. In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the Université Lille II, France.

Warren WinkelmanSenior Medical Director and Head of Medical Innovation, Nestlé Skin Health (SHIELD), USA

Warren J. Winkelman, MD, PhD, MBA, FAAD, FRCPC is Senior Medical Director and Head of Medical Innovation for the Nestle Skin Health

SHIELD global network. He is a board-certified dermatologist with more than 25 years’ experience in patient care, medical education, and research, and with over 10 years of corporate medical affairs leadership experience at Schering-Plough, Merck, Janssen and Galderma. Warren holds a PhD in ehealth innovation from the University of Toronto and an MBA in healthcare administration from SUNY-Binghamton School of Management. He was awarded a Canadian Institutes of Health Research (CIHR) fellowship in ehealth innovation science, and has conducted research under the auspices of the Center for Global eHealth Innovation (Toronto), the Canadian Dermatology Foundation (CDF) and the National Research Council-Canada (NRC) to help promote the empowerment of patients living with chronic disease through technology.

Mark DemesmaekerVice President, Scientific AnalyticsPerkinElmer, Switzerland

Mark is a seasoned life science professional and business leader with 20 years of experience in pharmaceutical R&D, analytics and business

intelligence. He is an experienced team builder and business manager with a solid background in both, business and leading-edge science. In addition, he has a proven track record of R&D analytics projects sold and delivered to multiple global pharmaceutical, biotechnology and contract research organizations. Importantly, Mark is passionate about analytics challenges in the transforming healthcare ecosystem. In his current role as Global Vice President - Scientific Analytics at PerkinElmer Informatics, he leads PKIs Analytics business line & product strategy. Mark joined PerkinElmer from IBM where he led Life Science Analytics within the central EMEA region in close cooperation with the IBM Watson Health unit. Prior to IBM, Mark served as Managing Director EU and Asia operations at Integrated Clinical Systems, Inc. Mark also spent a significant part of his career with TIBCO Spotfire where his most recent role was Director of Industry Analytics. At Spotfire, Mark shaped the EMEA solution consulting group as well as the life science- and clinical practices. Prior to joining Spotfire, Mark served as Technical Officer in the department of Quality Assurance & Safety: Medicines at the World Health Organization (WHO) in Geneva, Switzerland. After having obtained a degree as licensed pharmacist at the University of Bonn, Germany, he spent several years conducting research and teaching at University of Kiel, School of Pharmacy, Germany, where he earned a Ph.D. in drug metabolism and pharmacokinetics.

Mark Davies, Modelling and Simulation ScientistRoche, Switzerland

Dr. Mark Davies is a computational biologist with strong experience and passion to improve how we work with and analyse datasets from different sources. Integrating this data from multiple sources, by using

visualisation and modelling & simulation techniques supports stakeholders, often from different disciplines to understand the entirety of their data. He gained his PhD in Biological Sciences (University of Warwick, UK). He has broad experience of experimental techniques, informatics and data visualisation and their applications to modelling and simulation gained from 12 years at AstraZeneca and later at the Computational Cardiovascular Science group at the University of Oxford. At AstraZeneca he led a team to develop and implement software for Safety Pharmacology for integrating multiple ion channel screening data. Mark is the Founder and Principal Consultant at QT Informatics and in his most recent role has worked with F. Hoffmann-La Roche in defining a strategy for in silico cardiac modelling approaches for drug safety evaluation.

Peter SpeyerGlobal Head of Real World Evidence SolutionsNovartis, Switzerland

Peter Speyer is Global Head of Real World Evidence Solutions at Novartis, responsible for managing and expanding Novartis’ Real World

Evidence data and technology infrastructure, as well as creating visualizations and apps to make the data useful across the organization. Prior to his role at Novartis, Peter was Chief Data & Technology Officer at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington in Seattle. In that role, he was responsible for obtaining and managing the data that fuel IHME’s research in global and public health, and for providing powerful computational infrastructure that enables cutting edge analytics. To make IHME’s data and research results useful for others, he directed the development of the Global Health Data Exchange (GHDx) and IHME’s innovative interactive data visualizations. Prior to joining IHME, Peter spent most of his career in strategy and product management positions in the media industry. He worked most recently in a number of leadership positions at image licensing company Corbis, including Director of Market Strategy and Director of Product Management. Before Corbis, Peter held positions in Corporate Strategy and the TV subsidiary RTL Television at German media giant Bertelsmann. Peter holds an MBA from Temple University in Philadelphia, USA, and a Master in Business and Engineering from the Karlsruhe Institute of Technology, Germany.

John GlasspoolEVP, Head of Corporate Strategy and Customer Operations, Baxalta, USAAs a seasoned pharmaceutical executive with over 25 years of experience in the industry, John has extensive experience in multiple line and staff functions in the US, UK, Europe, and global markets

through his roles of increasing responsibility at Scotia Pharmaceuticals, Johnson & Johnson, Novartis, Baxter, and Baxalta. This experience has helped him architect innovative approaches to patient-centered drug development within the companies he has served, such as the P5 planning process and patient access approach. He has led franchises with over $6B in sales and has launched over 10 products. He is regularly invited to expert panels and also serves on the Board of Directors of the Biotechnology Industry Organization (BIO). John holds 2 patents and has degrees in politics and international relations from the University of Staffordshire, UK, and in business administration from Oxford Brookes University with a focus on international marketing. Before joining the pharmaceutical industry, John owned a restaurant and small hotel. John lives in Hingham, MA with his wife Susan, daughter Samantha, and cat Sushi.

Nevenka DimitrovaCTO Genomics, Healthcare ITPhilips Research, USANevenka Dimitrova, Ph.D., is a CTO of Genome Informatics at Philips. She has been at Philips since 1995. With her technology passion and intrapreneurial mind, she has been in diverse areas of signal processing,

cognition, healthcare informatics, understanding of the content of the human genome. She has become interested in both sides of the coin: what computation can do for modeling in biological systems and what biology can do for computation.

Thomas WilckensChief Executive Officer, CSO & FounderInnVentis, IsraelThomas Wilckens is an MD and a serial entrepreneur. His current focus is the novel venture InnVentis and the convergence of multi-omics technologies with real-world clinical data to enable PRECISION

MEDICINE, Thomas is also the founder of the LinkedIn group PRECISION MEDICINE & Big DATA an Associate at deep innovation GmbH, a boutique consultancy headed by the fmr. Head Group R&D Vodafone. Before joining deep innovation, he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University before heading off to basic research as a scholar of the Max-Planck Society and the Max-Kade Foundation, NY. He held several postdoc positions at leading academic institutions before becoming an entrepreneur. Aside from his work in biomedicine and nowadays mobile ICT he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”. With regard to this project Thomas is an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai. Thomas is convinced that we will see a disruption of current therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in nano- and biotechnology; i.e. Precision Medicine will ultimately be supported by algorithms for diagnostics and therapeutic decision making and become available anywhere 24/7.

Here’s what your industry peers are saying about it!

“Thanks so much for putting together this informative and stimulating meeting! I found the format to be well suited for the exchange of ideas, and the level of expertise of the participants, high. In addition, the topic areas are extremely timely. The use of big data is perhaps the most important current topic in health care, with a huge amount of confusion occurring currently as to how to apply this new form of knowledge. This problem is amplified by the current senior people in the health field having, by in large, not been exposed to this form of information during their training or career development. As a result, forums such as yours are key for the creation of an intellectual framework for the proper use and incorporation of big data going forward.”

Head of Genomics & BioinformaticsNational Cancer Institute, National Institutes of Health, USA

Highly interactive “Big Data Leadership Forum” in London, this week! Congratulations to the organizers, the speakers, the chair-people ... and the very well informed and passionate audience!

Global Senior Medical Director Respiratory, Boehringer Ingelheim

“Thank you and all the organizers for the opportunity to present our work at this wonderful meeting. It was very informative and great to see where biotech and pharma are heading with big data retention and analysis. You all did a great job putting this together and I look forward to coming again in the future.”

Senior Scientist, Early-Phase Pharmaceutical Development, Genentech, USA

“This meeting turned out to be much better than I thought. Many high-profile and very relevant delegates from pharma all in one place, professional organizers and very intensive networking sessions. Remind me to do this again next year.”

Co-founderInsilico Medicine, Switzerland

R&D DATA INTELLIGENCELEADERS FORUM

' - 83 Simple Ways to Register for this event!

CALL:+421 232 662 621

Participant Registration Options

GROUP DISCOUNTS (reduced from standard rate)

NOTE: For group discounts to apply all delegates must register on the same day.

PaymentsPayment is due within 5 days of registering. A receipt will be issued within 5 days of receipt of payment. CancellationIf you have any questions or issues please contact operations@nextlevelpharma.comCancellations must be in writing and must be received by NextLevel in writing more than 10 business days prior to the event. Upon receipt of cancellation notice, NextLevel Pharma will issue a delegate credit voucher for the full amount of the payment to be used towards registration fees at any future NextLevel Pharma event held within 18 months from date of issuance (“expiration date”). All credit vouchers expire automatically expire on the Expiration Date and shall thereupon become void. If cancellation is received more than 30 calendar days before the event then the client is entitled to a 50% refund and the balance in the form of a delegate credit voucher. Participants are advised that credits for cancellations not received more than 5 days before the event will not receive credit vouchers, including cancellations due to weather and other causes beyond the registrant’s control. Substitutions are welcome and are free of charge. If for any reason NextLevel Pharma decides to cancel this conference, NextLevel Pharma accepts no responsibility for covering airfare, travel, hotel or other costs incurred by registrants, including delegates sponsors speakers and guests.Special needs: Any participants with special dietary requirements or who require access aids should notify NextLevel Pharma more than 2 weeks prior to the event.

Registration includes:

Includes event documentation (Folder + USB flash drive).

Complimentary invite to our very popular networking dinner for all event participants.

Full delegate list with email addresses of all participants.

Event Lunches & Networking breaks.

A word from the event’s producer: “Thanks very much to the speakers for their commitment to this event and to guiding me with the agenda development. Based on my discussions with the speakers and panelists I’m looking forward to a highly productive event with many strong, implementable take-home messages for our delegates. I look forward to meeting you in Basel.”

Best Regards,Jan Sagal,NextLevel Pharma

VISIT:www.nextlevelpharma.com

Dates & Venue:24th-26th January, 2017Ramada Plaza Hotel - Basel, Switzerland

Hotel Booking Information will be sent to participants upon registration.Get connected immediately

EMAIL:anastasiar@nextlevelpharma.com

Reg i s t r at ionOpt ions

Options Standard Rate

2 Day event pass € 2290*

3 Day event pass € 2790*

SEND SAVE OFF STANDARD RATE

2 participants 20% each3 participants 30% each4 + participants 40% each

*VAT Exemption: All registrations who do not supply a VAT or tax identification number when registering, will be charged 20% VAT on the delegate registration amount as per local tax laws.

Academics & Non-Profits (2day/3day)__________ €950/€1150*Consultants & Solution Providers (2day/3day) ____ €2290/€2790*

(For clarification please feel free to email sponsorship@nextlevelpharma.com)

This event is accredited and certified for Continuing Professional Development due to it’s informative, case-study based and high quality

content.

The CPD Certification enables participants to transparently use training budgets and ensures their participation in this event is a valuable use of their time and resources.CPD Certificates will be issued to all participants.

Please visit: cpduk.co.uk

REGISTRATION DETAILS - HOW TO REGISTER:

R&D DATA INTELLIGENCELEADERS FORUM

Ramada Plaza Hotel - Basel, SwitzerlandJanuary 24-26th, 2017

FOURTH ANNUAL | LIFE SCIENCE

Dear Valued Customer,NextLevel Pharma are experts in providing the ideal platform for your strategic benchmarking and networking opportunities. I am very confident that by attending this meeting, you will improve your understanding of “best practice” and enhance your strategic decision-making in this vital area.Luke Rogers, CEO, NextLevel Pharma

OPTION 1: Please complete this form and fax back to: FAX: +421 233 010 331OPTION 2: Scan and email to anastasiar@nextlevelpharma.comOPTION 3: Register online at www.nextlevelpharma.com (click here)

DELEGATE PACKAGES: (Please Select your Delegate Package)

Pharma & Biotech Companies: 3 DAY CONFERENCE: 2 DAY CONFERENCE:

1 Delegate T €2790* €2290*2 Delegates - 20% DISCOUNT €2232* Each €1832* Each3 Delegates - 30% DISCOUNT €1953* Each €1603* Each4+ Delegates - 40% DISCOUNT €1674* Each €1374* Each

Other Organisations 3 DAY CONFERENCE: 2 DAY CONFERENCE: Academic (full-time only) €1150* Each €950* EachPayers & HTA Organisations €499* Each €499* EachConsultants & Solution Providers €2790* Each €2290* Each

CAN’T ATTEND?Event video recordings & documentation (only) _____ €799Event documentation (only) __________________ €399

nExT lEvEl Pharma conference agreement terms & conditions of Booking:1. Registration fees include programme materials, food and refreshments.2. Once a completed registration form has been received, full payment is required within 5 working days from

receipt of invoice. A receipt will be issued following payment.3. The client recognises that NextLevel Pharma organises high quality events, with strictly limited numbers of

attendees and incurs expenses as a result. NextLevel Pharma relies on all it’s clients to honour the agreement and make the required payment in order to guarantee the conference’s success.

4. Cancellation & Substitutions: Upon receipt of payment, substitutions of delegates can be made at any time before the meeting at no further cost. Once a completed registration form has been received any cancellations will result in a 50% cancellation fee. Cancellations received only 1 month before the conference date cannot be refunded whatsoever. In the result of a cancellation, NextLevel Pharma is willing to provide a delegate credit at full value to the client at any time within 7 days of the event taking place, upon receiving full payment and written notice of non-attendance. Any cancellations within 7 days of the event, or delegates who do not attend to the event (no-show), will receive a delegate credit for 50% of their registration fee to be used for future NextLevel events. Non-attendance or non-payment does not make this contract void. Payment is always required once the registration form has been received. Payment must be received before the start of the event.

5. * For group discounts to apply all delegates must register on the same day.

6. Whilst all reasonable care and effort has been made, NextLevel Pharma reserves the right to alter the programme content without notice. If, for any reason NextLevel Pharma decides to cancel, postpone or merge this conference with another conference, NextLevel Pharma is not responsible for covering hotel, airfare, or other expenses incurred by clients. The conference fee can be credited to a future conference.

7. Intellectual Property & Copyright. All NextLevel Pharma materials in relation to this event are exclusively reserved and any unauthorised duplication, publication or distribution is strictly prohibited.

8. This agreement shall be governed in accordance with the law of the Slovak Republic and the parties submit to the exclusive jurisdiction of the Slovak Courts. However only NextLevel Pharma is entitled to waive this right and submit to the jurisdiction of the courts in which the client’s office is located.

9. Client information is kept by NextLevel Pharma and used by NextLevel Pharma to keep clients informed of other related NextLevel Pharma products which may be of interest. If the client does not wish to be contacted further, please tick this box ( ). Your information may be shared with selected event sponsors so that they may share their information with you. If the client does not wish to be contacted by selected sponsors, please tick this box ( ).

10. NextLevel Pharma is thankful of client feedback at our events. In some situations, quotes & testimonials made by clients, may be used by NextLevel Pharma in future marketing literature. If you do not wish to be quoted, please tick this box ( ).

11. *VAT Exemption: All registrations who do not supply a VAT or tax identification number when registering, will be charged 20% VAT on the delegate registration amount as per local tax laws.

*All prices are in Euros

Please select your topic-focused streams (Day 2):STREAM 1: DISCOVERY & OMICS DATA EXCELLENCESTREAM 2: CLINICAL & PATIENT-LEVEL DATA EXCELLENCE

Please select your topic-focused streams (Day 3) - if attending:STREAM A: R&D IT & BIOINFORMATICSSTREAM B: DIGITAL R&D HEALTH COLLABORATIONS

Organisation: ________________________________________Address: ___________________________________________City: ________________________ Country: _______________Phone: _____________________________________________VAT/Tax ID Number: __________________________________This number is required for VAT exemption. (If not supplied, then 20% VAT will be applied.)

COMPANY INFORMATIONPlease write in BLOCK CAPITALS

Please debit my card (circle one):Visa Mastercard/Eurocard Amex Diner’s Club

Upon receipt of this registration NextLevel Pharma will send you a secure link requesting your credit card details.

Registration includes:Includes event documentation (Folder + USB flash drive).

Complimentary invite to our very popular networking dinner for all event participants.

Full delegate list with email addresses of all participants.

Event Lunches & Networking breaks.

*VAT Exemption: All registrations who do not supply a VAT or tax identification number when registering, will be charged 20% VAT on the delegate registration

amount as per local tax laws.

DELEGATE 1Name: _____________________________________________Job Title: ___________________________________________Email: _____________________________________________

DELEGATE 2Name: _____________________________________________Job Title: ___________________________________________Email: _____________________________________________

DELEGATE 3Name: _____________________________________________Job Title: ___________________________________________Email: _____________________________________________

CREDIT CARD PAYMENT:

CONFIRMATION OF REGISTRATION:

I agree to the NextLevel Pharma Terms and Conditions listed on this page. I am authorized to sign on behalf of my organisation.Name: ________________________________________Job Title: ______________________________________Date: ________________________________________Signature: _____________________________________

DELEGATE INFORMATION